ArticlemBio2020
Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 41 citations in OpenAlex.
- Disruption of the CD47-SIRPα Axis Causes Profound Reduction of Parasitaemia in Mice Infected With Babesia microti.Parasite immunology · 2026Article
- Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection.PLoS biology · 2026Article
- Targeting the CD47-SIRPα Axis in Atherosclerosis: From Pathogenesis to Therapeutic Implications.Journal of inflammation research · 2026Review
- CD47 monoclonal antibodies differ in their capacity to induce immune response.European journal of microbiology & immunology · 2025Article
- Article
- Loss of NR2F6 Protects from Salmonella Typhimurium Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Endoplasmic reticulum: the target of chlamydial manipulation.Archives of microbiology · 2025Review
- CD47 and thrombospondin-1 contribute to immune evasion byProceedings of the National Academy of Sciences of the United States of America · 2024Article
- P66 is a bacterial mimic of CD47 that binds the anti-phagocytic receptor SIRPα and facilitates macrophage evasion bybioRxiv : the preprint server for biology · 2024Article
- Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection.Journal of translational medicine · 2023Article
- Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers.Heliyon · 2023Review
- Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023Review
- Practical Mouse Model to Investigate Therapeutics for Staphylococcusaureus Contaminated Surgical Mesh Implants.The Journal of surgical research · 2023Article
- Simulation of COVID-19 symptoms in a genetically engineered mouse model: implications for the long haulers.Molecular and cellular biochemistry · 2023Article
- Host-directed therapy for bacterial infections -Modulation of the phagolysosome pathway.Frontiers in immunology · 2023Review
- CD47 restricts antiviral function of alveolar macrophages during influenza virus infection.iScience · 2022Article
- CD47/SIRPα axis: bridging innate and adaptive immunity.Journal for immunotherapy of cancer · 2022Review
- Proteomic characterization of phagocytic primary human monocyte-derived macrophages.RSC chemical biology · 2022Article
- New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells.Viruses · 2022Review
- CD47 antibody protects mice from doxorubicin-induced myocardial damage by suppressing cardiomyocyte apoptosis.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 5 institutions in 2 countries.
Michal Caspi Tal *Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Laughing Bear Torrez Dulgeroff *Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Lara Myers *Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Lamin B ChamInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Katrin D Mayer-BarberLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Andrea C BohrerLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ehydel CastroLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ying Ying YiuInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Cesar Lopez AngelDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Ed PhamDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Aaron B CarmodyResearch Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Ronald J MesserLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Eric GarsDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Jens KortmannGenentech Inc., South San Francisco, California, USA.
Maxim MarkovicInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Michaela HasenkrugLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Karin E PetersonLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Clayton W WinklerLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Tyson A WoodsLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Paige HansenInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Sarah GallowayInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Dhananjay WaghStanford Functional Genomics Facility, Stanford University School of Medicine, Stanford, California, USA.
Benjamin J FramDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Thai NguyenDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Daniel CoreyInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Raja Sab KalluruDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Niaz BanaeiDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Jayakumar RajadasBiomaterials and Advanced Drug Delivery Laboratory, Cardio Vascular Institute, Stanford University School of Medicine, Stanford, California, USA.
Denise M MonackDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Aijaz AhmedDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Debashis SahooDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Mark M DavisDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Jeffrey S GlennDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Tom AdomatiInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Karl S LangInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Irving L Weissman *Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA Irv@stanford.edu khasenkrug@nih.gov.
Kim J Hasenkrug *Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA Irv@stanford.edu khasenkrug@nih.gov.ORCID 0000-0001-8523-4911
Stanford University · USNational Institutes of Health · USUniversity of Duisburg-Essen · DEUniversity of California San Diego · USUniversity of California, San Francisco · US
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MTranslational Incubator CoreU19AI109662 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2014 to 2019
$28.6MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MInnate inflammatory responses during pulmonary infectionsZIAAI001207 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MAYER-BARBER, KATRIN · 2015 to 2025
$13.6MImmunology And Pathology Of Acute Murine Leukemia Virus InfectionsZIAAI000753 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2022
$8.1MInterrogation of individual cells to identify progenitors and their nichesU01HL099999 · NHLBI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2009 to 2015
$7.8MMOLECULAR CHARACTERIZATION OF ACUTE MYELOID LEUKEMIAR01CA086017 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2000 to 2015
$5.5MMacrophage Polarization in Response to Infections and InflammationR01AI155696 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, SAHOO, DEBASHIS · 2020 to 2024
$4.9MSummer Student Research on the Application of Boolean AnalysisR01GM138385 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SAHOO, DEBASHIS · 2020 to 2023
$2.0MPrecision therapeutics of inflammatory bowel disease guided by Boolean logicUG3TR003355 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2020 to 2022
$937kInterrogating inflammatory responses to SARS-CoV-2 infection in vivoZIAAI001293 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MAYER-BARBER, KATRIN · 2020 to 2025
$831kSARS-CoV-2 Immunology and TherapeuticsZIAAI001277 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2020 to 2022
$109kNCATS NIH HHS UG3 TR003355NCI NIH HHS R01 CA086017NHLBI NIH HHS U01 HL099999NIAID NIH HHS 1 F32 AI124558-01NIAID NIH HHS F32 AI124558NIAID NIH HHS R01 AI155696NIAID NIH HHS T32 AI007290NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI109662NIDDK NIH HHS F30 DK099017NIGMS NIH HHS R01 GM138385
Abstract
It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 "don't eat me" signal, which slows the phagocytic uptake of dying and viable cells as well as downstream antigen-presenting cell (APC) functions. A CD47 mimic that acts as an essential virulence factor is encoded by all poxviruses, but CD47 expression on infected cells was found to be upregulated even by pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that encode no mimic. CD47 upregulation was revealed to be a host response induced by the stimulation of both endosomal and cytosolic pathogen recognition receptors (PRRs). Furthermore, proinflammatory cytokines, including those found in the plasma of hepatitis C patients, upregulated CD47 on uninfected dendritic cells, thereby linking innate modulation with downstream adaptive immune responses. Indeed, results from antibody-mediated CD47 blockade experiments as well as CD47 knockout mice revealed an immunosuppressive role for CD47 during infections with lymphocytic choriomeningitis virus and
Indexed as
A549 CellsAdaptive ImmunityAnimalsBetacoronavirusCD47 AntigenCell Line, TumorCytokinesFemaleHumansImmunity, InnateImmunomodulationLymphocytic choriomeningitis virusMaleMiceMice, Inbred C57BLMice, KnockoutCD47 AntigenCytokinesReceptors, Pattern RecognitionCD47host responseimmune checkpointinnate immunitypathogen recognition receptors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.